Lactate dehydrogenase-elevating virus infection at the sensitization and challenge phases reduces the development of delayed eosinophilic allergic rhinitis in BALB/c mice.
The present study was conducted to determine whether lactate dehydrogenase-elevating virus (LDV) infection at the sensitization and challenge phases affect the development of delayed allergic eosinophilic rhinitis induced by ovalbumin (OVA) in BALB/c mice (DAR group). Compared to the DAR group, LDV infection at the priming (DAR/LDVs group) and immunizing (DAR/LDVc group) phases reduced the induction of eosinophils in the bone marrow (BM) and/or blood. However, the number of eosinophils in the BM was not affected in the DAR/LDVc group. In addition, total blood IgE values were reduced in the DAR/LDVs but not the DAR/LDVc groups. Compared to the production of cytokines from splenic cells and blood IgE values in the DAR group, OVA-specific IL-4 and IFN-gamma productions and IgE values were reduced in the DAR/LDVs, whereas OVA-specific IFN-gamma and IL-4 productions were increased and decreased, respectively in the DAR/LDVc,but not the DAR/LDVs groups. Both DAR/LDVs and DAR/LDVc groups reduced the development of eosinophilic rhinitis associated with reduced VCAM-1 expression on endothelium in blood vessels and ICAM-1 expression on nasal respiratory epithelium at inflamed areas. The present study suggests that LDV infection at the sensitization phase may reduce the development of T helper (Th) 1 and Th2 responses, whereas LDV infection at the challenge phase may inhibit the development of Th2 response by shifting to Th1 response. These may be responsible for the reduction of the development of DAR by LDV infection.
Sasaki
Y
Y
Laboratory of Veterinary Pathology, Yamaguchi University, Yamaguchi, Japan.
Hayashi
T
T
Hasegawa
K
K
D000818:Animals; D018174:Arterivirus Infections / Q000276:immunology*; D001985:Bronchial Provocation Tests; D004195:Disease Models, Animal; D004802:Eosinophilia / Q000276:immunology* / Q000821:virology; D005260:Female; D007114:Immunization; D007073:Immunoglobulin E / Q000096:biosynthesis; D007155:Immunologic Factors / Q000276:immunology; D007371:Interferon-gamma / Q000096:biosynthesis; D007772:Lactate dehydrogenase-elevating virus / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000276:immunology / Q000821:virology; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology* / Q000517:prevention & control / Q000821:virology*; D013045:Species Specificity; D013047:Specific Pathogen-Free Organisms / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology / Q000821:virology; D018418:Th2 Cells / Q000276:immunology / Q000821:virology
D007155:Immunologic Factors; D007073:Immunoglobulin E; D007371:Interferon-gamma; D010047:Ovalbumin